Launching the ReDS-SAFE HF II Trial: A New Era in Heart Failure Treatment
Launching the ReDS-SAFE HF II Trial: A New Era in Heart Failure Treatment
In a groundbreaking announcement at the recent THT conference, Dr. Jesus Alvarez-Garcia, MD, PhD, who leads the Advanced Heart Failure Unit at Ramón y Cajal Hospital in Madrid, unveiled the initiation of the ReDS-SAFE HF II trial. This extensive research project is set to validate the innovative approaches for managing heart failure (HF) using ReDS (Remote Dielectric Sensing) technology.
Overview of the Trial
This multicenter trial aims to enroll over 1,000 patients across 24 medical centers in Spain. Its primary goal is to verify whether ReDS-guided heart failure management can outshine standard care protocols, particularly in improving patient outcomes within a 30-day window following hospitalization. The ReDS-guided approach will involve patients receiving daily measurements of their ReDS during their time in the hospital, alongside an additional assessment at a follow-up visit scheduled for one week after discharge. This method is designed to optimize the management of pulmonary congestion and minimize complications associated with heart failures during the critical post-discharge phase.
This initiative is not an isolated effort; it builds upon the success of the previous ReDS-SAFE HF study, which showcased promising outcomes. This earlier study, presented by Dr. Alvarez-Garcia, evaluated 100 patients experiencing acute decompensated heart failure (ADHF) and demonstrated a striking 90.6% reduction in mortality, readmissions, and unplanned visits related to heart failure within 30 days post-discharge. Notably, patients under ReDS management showed a significant decline in ReDS values during their hospital stay, indicating enhanced recovery compared to those receiving standard care.
The validation of these groundbreaking findings aims to introduce ReDS-guided management as a new standard of care in heart failure treatment. This monumental endeavor is supported by several prominent institutions including the Government of Spain, the Spanish Society of Cardiology, and Sensible Medical.
Expectations and Future Impact
Reflecting on the excitement surrounding the ReDS-SAFE HF II trial, Dr. Alvarez-Garcia remarked, “We are thrilled to expand our study to over 1,000 patients across multiple centers. This trial is pivotal in demonstrating how ReDS-guided management can significantly improve heart failure outcomes. By offering a personalized approach during hospitalization and the vulnerable post-discharge period, this initiative strives to mitigate the risks of rehospitalization and enhance the quality of life for patients battling heart failure.”
About ReDS Technology
The ReDS™ Pro System is a non-invasive technological advancement designed for the assessment of pulmonary congestion. It operates seamlessly to empower healthcare professionals globally in their efforts to better manage heart failure conditions. Through this innovative device, managed by trained physicians and nurses, the objective remains to prevent readmissions by providing precise monitoring.
Sensible Medical Innovations
Founded on a mission to develop effective solutions in lung fluid management, Sensible Medical Innovations is at the forefront of this transformative approach. The company has pioneered the ReDS medical radar technology, a method originally derived from defense sector innovations for
Topics Other）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.